Back to Journals » Therapeutics and Clinical Risk Management » Volume 11

A randomized crossover study comparing trehalose/hyaluronate eyedrops and standard treatment: patient satisfaction in the treatment of dry eye syndrome

Authors Pinto-Bonilla JC, del Olmo-Jimeno A, Llovet-Osuna F, Hernández-Galilea E

Received 6 November 2014

Accepted for publication 7 February 2015

Published 13 April 2015 Volume 2015:11 Pages 595—603

DOI https://doi.org/10.2147/TCRM.S77091

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Garry Walsh

Juan Carlos Pinto-Bonilla,1 Alberto del Olmo-Jimeno,2 Fernando Llovet-Osuna,3 Emiliano Hernández-Galilea4

1Department of Corneal, Refractive, and Cataract Surgery, European Ophthalmological Institute, Clínica Baviera, Pamplona, Navarra, Spain; 2Optometry Department, European Ophthalmological Institute, Clínica Baviera, Pamplona, Navarra, Spain; 3Department of Refractive and Cataract Surgery, European Ophthalmological Institute, Clínica Baviera, Madrid, Madrid, Spain; 4Ophthalmology Department, Hospital Clínico Universitario de Salamanca, Universidad de Salamanca, Salamanca, Salamanca, Spain

Abstract: Dry eye is a common disorder in routine ophthalmological practice, and a better understanding of the complex pathophysiology is leading to improved treatment. Thealoz Duo® is a novel artificial tear preparation containing two active ingredients: Trehalose, a naturally occurring disaccharide with anhydrobiotic functions in many organisms, and hyaluronate, a widely distributed anionic glycosaminoglycan polysaccharide with lubricative and water-retaining properties in biological systems. In a randomized, single center, open label, crossover study, 17 adult patients with moderate-to-severe dry eye syndrome were randomized to treatment with Thealoz Duo® (combining trehalose and hyaluronic acid) or Systane®. Patients received 7 days of treatment. The primary efficacy variable was patient satisfaction evaluated by a 0–100 visual analog scale evaluated on days 0 and 7 of treatment. Secondary parameters included ocular surface disease index (OSDI), symptoms of dry eye, ocular staining scores (fluorescein and lissamine green), ocular clinical signs, Schirmer test, tear breakup time, and global efficacy assessed by the patient and the investigator. Seventeen patients were included. Patient satisfaction improved from 44.5±19.0 to 70.2±19.2 mm during Thealoz Duo® treatment and from 47.2±23 to 57.1±19.1 mm during Systane® treatment (P=0.043, mixed-effects analysis of covariance). Two secondary efficacy parameters (dry eye symptoms and the impact of their symptoms on work) showed statistically significant advantages for Thealoz Duo® over Systane®. There were no statistically significant advantages for Systane® over Thealoz Duo® for any measured parameter. No adverse events were reported. Thealoz Duo® appears to be an effective combination of two active ingredients for the treatment of dry eye and is at least as effective as Systane®.

Keywords: dry eye, Thealoz Duo®, Systane®, patients, eyedrop, tears

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction [Corrigendum]

Muñoz Negrete FJ, Lemij HG, Erb C

Clinical Ophthalmology 2017, 11:887-888

Published Date: 11 May 2017

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction

Muñoz Negrete FJ, Lemij HG, Erb C

Clinical Ophthalmology 2017, 11:557-566

Published Date: 21 March 2017

Patient satisfaction with glaucoma therapy: reality or myth?

Lemij HG, Hoevenaars JGMM, van der Windt C, Baudouin C

Clinical Ophthalmology 2015, 9:785-793

Published Date: 4 May 2015

A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness

Bremond-Gignac D, Messaoud R, Lazreg S, Speeg-Schatz C, Renault D, Chiambaretta F

Clinical Ophthalmology 2015, 9:725-732

Published Date: 20 April 2015

European survey on the opinion and use of micronutrition in age-related macular degeneration: 10 years on from the Age-Related Eye Disease Study

Aslam T, Delcourt C, Holz F, García-Layana A, Leys A, Silva RM, Souied E

Clinical Ophthalmology 2014, 8:2045-2053

Published Date: 10 October 2014

Evaluation of the efficacy, safety, and acceptability of an eyelid warming device for the treatment of meibomian gland dysfunction

Benitez del Castillo JM, Kaercher T, Mansour K, Wylegala E, Dua H

Clinical Ophthalmology 2014, 8:2019-2027

Published Date: 6 October 2014

Latanoprost in the treatment of glaucoma

Alm A

Clinical Ophthalmology 2014, 8:1967-1985

Published Date: 26 September 2014

Use of preservative-free hyaluronic acid (Hylabak®) for a range of patients with dry eye syndrome: experience in Russia

Brzhesky VV, Maychuk YF, Petrayevsky AV, Nagorsky PG

Clinical Ophthalmology 2014, 8:1169-1177

Published Date: 18 June 2014

Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection

Romero-Aroca P, Sararols L, Arias L, Casaroli-Marano RP, Bassaganyas F

Clinical Ophthalmology 2012, 6:1595-1599

Published Date: 9 October 2012

Tolerability and acceptability of Blephagel: a novel eyelid hygiene aqueous gel

Doan S

Clinical Ophthalmology 2012, 6:71-77

Published Date: 11 January 2012

Do neurologists in Germany adhere to the national Parkinson's disease guideline?

Sabrina Schröder, Daniel Kuessner, Guy Arnold, et al

Neuropsychiatric Disease and Treatment 2011, 7:103-110

Published Date: 7 March 2011

Readers of this article also read:

Perioperative management of hemophilia patients receiving total hip and knee arthroplasty: a complication report of two cases

Tateiwa T, Takahashi Y, Ishida T, Kubo K, Masaoka T, Shishido T, Sano K, Yamamoto K

Therapeutics and Clinical Risk Management 2015, 11:1383-1389

Published Date: 15 September 2015

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010